Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals · 2026
Circulating KIM-1 as a prognostic biomarker and predictor of systemic treatment response in renal cell carcinoma: a systematic review and meta-analysis.
СтатьяСистематический обзорМетаанализНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Febriyanto Toni, Hutajulu Yosua Yerico, Yogahutama Noka, Wijaya Wynne, Hendri Ahmad Zulfan
Аннотация
BACKGROUND: Renal cell carcinoma (RCC) exhibits heterogeneity and variable responses to systemic therapy. Kidney injury molecule-1 (KIM-1) has emerged as a biomarker in RCC, but its prognostic and treatment-response value has not been quantified. This review and meta-analysis evaluated whether baseline KIM-1 predicts survival in RCC and whether post-treatment changes in KIM-1 reflect systemic therapy response.
METHODS: A search of PubMed, Embase and the Cochrane Library was conducted through November 2025. Eligible studies measured serum or plasma KIM-1 in RCC and reported survival or treatment-response outcomes. Hazard ratios (HRs) with 95% confidence intervals (CIs) were pooled.
RESULTS: Eight studies including 3002 patients met inclusion criteria. High baseline KIM-1 was associated with worse survival (HR 1.44, 95% CI 1.27-1.62) and disease-free survival (HR 1.72, 95% CI 1.45-2.04), with no heterogeneity (I2 = 0%). Declines in KIM-1 after systemic therapy were associated with improved progression-free survival (HR 0.55, 95% CI 0.32-0.94; I2 = 71.5%) and improved disease-free survival (HR 0.66, 95% CI 0.50-0.87).
CONCLUSIONS: Elevated baseline circulating KIM-1 indicates higher RCC recurrence and mortality risk, while post-treatment declines may reflect therapeutic response. Preliminary evidence suggests KIM-1 prognostic and predictive value for RCC biomarker, though further validation is required due to lower certainty.
METHODS: A search of PubMed, Embase and the Cochrane Library was conducted through November 2025. Eligible studies measured serum or plasma KIM-1 in RCC and reported survival or treatment-response outcomes. Hazard ratios (HRs) with 95% confidence intervals (CIs) were pooled.
RESULTS: Eight studies including 3002 patients met inclusion criteria. High baseline KIM-1 was associated with worse survival (HR 1.44, 95% CI 1.27-1.62) and disease-free survival (HR 1.72, 95% CI 1.45-2.04), with no heterogeneity (I2 = 0%). Declines in KIM-1 after systemic therapy were associated with improved progression-free survival (HR 0.55, 95% CI 0.32-0.94; I2 = 71.5%) and improved disease-free survival (HR 0.66, 95% CI 0.50-0.87).
CONCLUSIONS: Elevated baseline circulating KIM-1 indicates higher RCC recurrence and mortality risk, while post-treatment declines may reflect therapeutic response. Preliminary evidence suggests KIM-1 prognostic and predictive value for RCC biomarker, though further validation is required due to lower certainty.